BMY Oct 2024 55.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:30AM EDT. Market open.
Loading interactive chart...
- Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., May 29, 2024--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line...
- ACCESSWIRE
ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 /Originally published on Bristol Myers Squibb News & Perspectives Globally, communities are struggling to support growing healthcare needs. This is especially true in regions with limited financial resources, ...
- Business Wire
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
PRINCETON, N.J., May 23, 2024--Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications....
© 2024 Yahoo. All rights reserved.